💊FDA PHARMA updates
Roche – FDA grants Roche’s Avastin full approval for most aggressive form of brain cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease).
https://www.roche.com/investors/updates/inv-update-2017-12-06.htm
CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival
News Release /ONO PHARMACEUTICAL CO., LTD.
http://www.ono.co.jp/eng/news/pdf/sm_cn171206.pdf